Page 7 - Victorian Heart Hospital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Victorian heart hospital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Victorian Heart Hospital Today - Breaking & Trending Today

World first drug to target form of previously

Simultaneous presentation at European Cardiology Conference and publication in JAMA will detail the world's first oral drug for the treatment of a type of high cholesterol - called Lp(a) - that is a potentially more dangerous version of the so called "bad" cholesterol, LDL, because it is stickier and may be more likely to cause blockages and blood clots in your arteries.

It is estimated that up to 20% of people worldwide have high levels of Lp(a), which is associated with a person's risk of experiencing a heart attack, strokes or other serious cardiac event. Importantly Lp(a) can be present even in younger adults and otherwise healthy people with no other known cardiovascular risks - and often remains undetected until a cardiac event has occurred. ....

South Australia , Noord Holland , Stephen Nicholls , Eli Lilly , Victorian Heart Hospital At Monash Health , Monash Health , Method Of Research , European Society Of Cardiology Congress , Monash Victorian Heart Institute , Monash University , Monash Health Is Victoria , Monash University Victorian Heart Institute , Professor Stephen Nicholls , Victorian Heart Institute , Victorian Heart , Victorian Heart Hospital , European Society , Cardiology Congress , Cleveland Clinic , Heart Hospital , Monash Victorian Heart , Oral Small Molecule Inhibitor , Randomized Clinical ,

Dr Stephen Nicholls: How a Cardiovascular Trial Addresses Long-Term Practicality of GLP-1–Based Weight Loss

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, explains how he works closely with patients and study sites in SURPASS-CVOT to avoid weight loss drug discontinuation and weight regain. ....

Stephen Nicholls , Monash University , Victorian Heart Hospital , Surpass Cvot ,

How SURPASS-CVOT Spotlights Tirzepatide for Cardiovascular Outcomes: Dr Stephen Nicholls

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide. ....

South Australia , Stephen Nicholls , Monash University , Victorian Heart Hospital ,